Ramucirumab as a second-line treatment for hepatocellular carcinoma: reaching out further to patients with elevated alpha-fetoprotein

摘要：

Hepatocellular carcinoma (HCC) occurs at a rate of 3-5％per year in patients with compensated cirrhosis, and itoften represents the first disease complication and themain cause of death in these patients (1). Surveillance forHCC is recommended by all liver disease associations,as it increases patient survival mainly as a result of earlydiagnosis of the tumour, allowing most patients to conveyto curative treatments (2,3).

所属期刊栏目：8

在线出版日期：2020-04-03（万方平台首次上网日期，不代表论文的发表时间）

页数：共4页

页码：515-518